Back to Search Start Over

Comprehensive analysis identifies CLEC1B as a potential prognostic biomarker in hepatocellular carcinoma

Authors :
Qiangan Jing
Chen Yuan
Chaoting Zhou
Weidong Jin
Aiwei Wang
Yanfang Wu
Wenzhong Shang
Guibing Zhang
Xia Ke
Jing Du
Yanchun Li
Fangchun Shao
Source :
Cancer Cell International, Vol 23, Iss 1, Pp 1-17 (2023)
Publication Year :
2023
Publisher :
BMC, 2023.

Abstract

Abstract Background C-type lectin domain family 1 member B (CLEC1B, encoding the CLEC-2 protein), a member of the C-type lectin superfamily, is a type II transmembrane receptor involved in platelet activation, angiogenesis, and immune and inflammatory responses. However, data regarding its function and clinical prognostic value in hepatocellular carcinoma (HCC) remain scarce. Methods The expression of CLEC1B was explored using The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. RT-qPCR, western blot, and immunohistochemistry assays were employed to validate the downregulation of CLEC1B. Univariate Cox regression and survival analyses were used to evaluate the prognostic value of CLEC1B. Gene Set Enrichment Analysis (GSEA) was conducted to investigate the potential association between cancer hallmarks and CLEC1B expression. The TISIDB database was applied to search for the correlation between immune cell infiltration levels and CLEC1B expression. The association between CLEC1B and immunomodulators was conducted by Spearman correlation analysis based on the Sangerbox platform. Annexin V-FITC/PI apoptosis kit was used for the detection of cell apoptosis. Results The expression of CLEC1B was low in various tumors and exhibited a promising clinical prognostic value for HCC patients. The expression level of CLEC1B was tightly associated with the infiltration of various immune cells in the HCC tumor microenvironment (TME) and positively correlated with a bulk of immunomodulators. In addition, CLEC1B and its related genes or interacting proteins are implicated in multiple immune-related processes and signaling pathways. Moreover, overexpression of CLEC1B significantly influenced the treatment effects of sorafenib on HCC cells. Conclusions Our results reveal that CLEC1B could serve as a potential prognostic biomarker and may be a novel immunoregulator for HCC. However, its function in immune regulation should be further explored.

Details

Language :
English
ISSN :
14752867
Volume :
23
Issue :
1
Database :
Directory of Open Access Journals
Journal :
Cancer Cell International
Publication Type :
Academic Journal
Accession number :
edsdoj.528dea1340468e86eb5ac9d4ae1dda
Document Type :
article
Full Text :
https://doi.org/10.1186/s12935-023-02939-1